person · Reporting owner
McMurdo Matthew Charles
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapForce Inc.OPGN · Entity 9776 | Director | April 11, 2024 | April 12, 2024 |
| FiEE, Inc.MINM · Entity 7395 | Director | September 26, 2024 | October 01, 2024 |
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | February 26, 2026 | February 26, 2026 |
| TITAN PHARMACEUTICALS INCTTNP · Entity 74432 | Director | October 25, 2023 | October 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapForce Inc.
Report date April 11, 2024 · Filed April 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2024-04-11 transaction · row 1
1 source rowRow 1 · 2024-04-11 · Grant · Acquired 100,000 · Balance 100,000 F1: Shares of restricted stock issued pursuant to the 2015 Equity Incentive Plan of OpGen, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of restricted stock issued pursuant to the 2015 Equity Incentive Plan of OpGen, Inc.
FiEE, Inc.
Report date September 26, 2024 · Filed October 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 184,364 |
Reported balance
After 2024-09-26 transaction · row 1
1 source rowRow 1 · 2024-09-26 · Grant · Acquired 159,364 · Balance 184,364 F1: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc.
Indaptus Therapeutics, Inc.
Report date February 26, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 25,000 |
TITAN PHARMACEUTICALS INC
Report date October 25, 2023 · Filed October 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,250 |
Reported balance
After 2023-10-25 transaction · row 1
1 source rowRow 1 · 2023-10-25 · Grant · Acquired 16,250 · Balance 66,250 F1: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 26, 2024 Filed Oct 1, 2024 16:48 UTC | FiEE, Inc. MINM · Entity 7395 | GrantCommon Stock | 159,364 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-24-002198 · form412227016mcm_10012024.xml · nonDerivative · entry 1 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,364 F1 · price: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 17:04 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-24-000830 · form412227017mcm_04122024.xml · nonDerivative · entry 1 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: Shares of restricted stock issued pursuant to the 2015 Equity Incentive Plan of OpGen, Inc. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 17:11 UTC | FiEE, Inc. MINM · Entity 7395 | GrantCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-24-000128 · form412227016mcm_01242024.xml · nonDerivative · entry 1 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 16:31 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-23-002395 · form413531002mcm_10262023.xml · nonDerivative · entry 1 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,250 F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 17:43 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-23-001754 · form413531mcm_07282023.xml · nonDerivative · entry 1 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. Read SEC document |
| July 26, 2023 Filed Jul 31, 2023 19:42 UTC Amendment | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-23-001767 · form4a13531001mcm_07312023.xml · nonDerivative · entry 1 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. Read SEC document |
| June 29, 2023 Filed Jul 28, 2023 17:43 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000921895-23-001754 · form413531mcm_07282023.xml · derivative · entry 3 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2022-09-15 F3 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. F3 · date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. F3 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. Read SEC document |
| June 29, 2023 Filed Jul 28, 2023 17:43 UTC | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0000921895-23-001754 · form413531mcm_07282023.xml · derivative · entry 2 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-08-15 F2 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. F2 · date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. F2 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. Read SEC document |
| June 29, 2023 Filed Jul 31, 2023 19:42 UTC Amendment | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000921895-23-001767 · form4a13531001mcm_07312023.xml · derivative · entry 3 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-15 F4 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. F4 · date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. F4 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. F3 · derivative.expiration_date: This Form 4 is being amended to correct the expiration date of the options, which were incorrectly reported in the original report due to an inadvertent clerical error. Read SEC document |
| June 29, 2023 Filed Jul 31, 2023 19:42 UTC Amendment | TITAN PHARMACEUTICALS INC TTNP · Entity 74432 | GrantOption to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0000921895-23-001767 · form4a13531001mcm_07312023.xml · derivative · entry 2 McMurdo Matthew Charles · CIK 0001943108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-15 F2 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. F2 · date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. F2 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. F3 · derivative.expiration_date: This Form 4 is being amended to correct the expiration date of the options, which were incorrectly reported in the original report due to an inadvertent clerical error. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.